ACH-806 - CAS 870142-71-5
Catalog number: 870142-71-5
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
Molecular Weight:
ACH-806 is a Hepatitis C virus NS3 protein inhibitor. It can inhibit viral RNA replication in HCV replicon cells and is active in genotype 1 HCV-infected patients in a proof-of-concept clinical trial. But Phase-II for Hepatitis C treatment was discontinued.
GS-9132; N-(((4-(pentyloxy)-3-(trifluoromethyl)phenyl)amino)thioxomethyl)-3-Pyridinecarboxamide,
Soluble in DMSO
-20℃ Freezer
Quality Standard:
In-house standard
Shelf Life:
2 month in rt, long time
Canonical SMILES:
Current Developer:
Originator Achillion Pharmaceuticals
1.Selection of replicon variants resistant to ACH-806, a novel hepatitis C virus inhibitor with no cross-resistance to NS3 protease and NS5B polymerase inhibitors.
Yang W;Zhao Y;Fabrycki J;Hou X;Nie X;Sanchez A;Phadke A;Deshpande M;Agarwal A;Huang M Antimicrob Agents Chemother. 2008 Jun;52(6):2043-52. doi: 10.1128/AAC.01548-07. Epub 2008 Apr 14.
We have discovered a novel class of compounds active against hepatitis C virus (HCV), using a surrogate cellular system, HCV replicon cells. The leading compound in the series, ACH-806 (GS-9132), is a potent and specific inhibitor of HCV. The selection of resistance replicon variants against ACH-806 was performed to map the mutations conferring resistance to ACH-806 and to determine cross-resistance profiles with other classes of HCV inhibitors. Several clones emerged after the addition of ACH-806 to HCV replicon cells at frequencies and durations similar to that observed with NS3 protease inhibitors and NS5B polymerase inhibitors. Phenotypic analyses of these clones revealed that they are resistant to ACH-806 but remain sensitive to other classes of HCV inhibitors. Moreover, no significant change in the susceptibility to ACH-806 was found when the replicon cellular clones resistant to NS3 protease inhibitors and NS5B polymerase inhibitors were examined. Sequencing of the entire coding region of ACH-806-resistant replicon variants yielded several consensus mutations. Reverse genetics identified two single mutations in NS3, a cysteine-to-serine mutation at amino acid 16 and an alanine-to-valine mutation at amino acid 39, that are responsible for the resistance of the replicon variants to ACH-806.
2.Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients.
Kuntzen T;Timm J;Berical A;Lennon N;Berlin AM;Young SK;Lee B;Heckerman D;Carlson J;Reyor LL;Kleyman M;McMahon CM;Birch C;Schulze Zur Wiesch J;Ledlie T;Koehrsen M;Kodira C;Roberts AD;Lauer GM;Rosen HR;Bihl F;Cerny A;Spengler U;Liu Z;Kim AY;Xing Y;Schneidewind A;Madey MA;Fleckenstein JF;Park VM;Galagan JE;Nusbaum C;Walker BD;Lake-Bakaar GV;Daar ES;Jacobson IM;Gomperts ED;Edlin BR;Donfield SM;Chung RT;Talal AH;Marion T;Birren BW;Henn MR;Allen TM Hepatology. 2008 Dec;48(6):1769-78. doi: 10.1002/hep.22549.
Resistance mutations to hepatitis C virus (HCV) nonstructural protein 3 (NS3) protease inhibitors in <1% of the viral quasispecies may still allow >1000-fold viral load reductions upon treatment, consistent with their reported reduced replicative fitness in vitro. Recently, however, an R155K protease mutation was reported as the dominant quasispecies in a treatment-naïve individual, raising concerns about possible full drug resistance. To investigate the prevalence of dominant resistance mutations against specifically targeted antiviral therapy for HCV (STAT-C) in the population, we analyzed HCV genome sequences from 507 treatment-naïve patients infected with HCV genotype 1 from the United States, Germany, and Switzerland. Phylogenetic sequence analysis and viral load data were used to identify the possible spread of replication-competent, drug-resistant viral strains in the population and to infer the consequences of these mutations upon viral replication in vivo. Mutations described to confer resistance to the protease inhibitors Telaprevir, BILN2061, ITMN-191, SCH6 and Boceprevir; the NS5B polymerase inhibitor AG-021541; and to the NS4A antagonist ACH-806 were observed mostly as sporadic, unrelated cases, at frequencies between 0.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related HCV Products

CAS 1441674-54-9 Ledipasvir acetone

Ledipasvir acetone
(CAS: 1441674-54-9)

Ledipasvir is an inhibitor of hepatitis C virus NS5A.

CAS 876708-03-1 RO-9187

(CAS: 876708-03-1)

RO-9187 is a potent inhibitor of HCV virus replication in the replicon system. It is excellent substrates for deoxycytidine kinase and were phosphorylated with ...


GSK-2818713 is a second-generation inhibitor of hepatitis C virus (HCV) NS5A replication. Compared to daclatasvir, a first-generation NS5A replication complex i...

CAS 1216941-48-8 Paritaprevir

(CAS: 1216941-48-8)

Paritaprevir could inhibit viral phosphoprotein NS5A and is significant to viral replication and other activities. It also has been found to have potential effe...

CAS 817204-33-4 PSI-6130

(CAS: 817204-33-4)

PSI-6130 is a potent and selective inhibitor of HCV NS5B polymerase. It is metabolized to two pharmacologically active species in primary human hepatocytes.

CAS 630420-16-5 Asunaprevir

(CAS: 630420-16-5)

Asunaprevir is a potent hepatitis C virus (HCV) non-structural protein protease inhibitor currently in Phase III clinical trials for the treatment of HCV infect...

CAS 20724-73-6 2'-C-Methylcytidine

(CAS: 20724-73-6)

2'-C-Methylcytidine, also called as NM107, inhibits the replication of HCV RNA and exerts inhibitory activity and cytotoxicity against HCV 1b replicon cells (IC...

CAS 1377049-84-7 Velpatasvir

(CAS: 1377049-84-7)

Velpatasvir is a selective Hepatitis C virus NS 5 protein inhibitor originated by Gilead Sciences. It showed pan-genotypic activity and a high barrier to resist...

Chemical Structure

CAS 870142-71-5 ACH-806

Quick Inquiry

Verification code

Featured Items